Skip Navigation

COVID-19: We are vaccinating patients ages 12+. Learn more:

Vaccines, Boosters & Additional Doses | Testing | Patient Care | Visitor Guidelines | Coronavirus | Self-Checker | Email Alerts

 

Philips Respironics issued a recall for some CPAP and BiLevel PAP devices and mechanical ventilators. Learn more.

Find a Research Lab

Research Lab Results for immunotherapy

Displaying 11 to 15 of 15 results
Results per page:
  • Maureen Horton Lab

    Principal Investigator:
    Maureen Horton, M.D.
    Medicine

    The Maureen Horton Lab conducts research on pulmonary fibrosis through the use of both preclinical models and human trials. Our studies have helped to develop novel, genetic, tissue-specific models of immune dysfunction, which have aided in defining the immune regulation of fibrosis and in the development of treatment strategies. We have used T-cell skewing immunotherapy to prevent and reverse chemical-induced lung fibrosis and have conducted clinical trials for idiopathic pulmonary fibrosis (IPF), which led to one of the first treatments that helped to improve quality of life in IPF patients.

    Research Areas: interstitial lung diseases, idiopathic pulmonary fibrosis, pulmonary fibrosis, autoimmune diseases, occupational lung diseases, T cells
  • Molecular Oncology Laboratory

    Principal Investigator:
    Valsamo Anagnostou, M.D., Ph.D.
    Oncology

    Our Molecular Oncology lab seeks to understand the genomic wiring of response and resistance to immunotherapy through integrative genomic, transcriptomic, single-cell and liquid biopsy analyses of tumor and immune evolution. Through comprehensive exome-wide sequence and genome-wide structural genomic analyses we have discovered that tumor cells evade immune surveillance by elimination of immunogenic mutations and associated neoantigens through chromosomal deletions. Additionally, we have developed non-invasive molecular platforms that incorporate ultra-sensitive measurements of circulating cell-free tumor DNA (ctDNA) to assess clonal dynamics during immunotherapy. These approaches have revealed distinct dynamic ctDNA and T cell repertoire patterns of clinical response and resistance that are superior to radiographic response assessments. Our work has provided the foundation for a molecular response-adaptive clinical trial, where therapeutic decisions are made not based on imaging but b...ased on molecular responses derived from liquid biopsies. Overall, our group focuses on studying the temporal and spatial order of the metastatic and immune cascade under the selective pressure of immune checkpoint blockade with the ultimate goal to translate this knowledge into “next-generation” clinical trials and change the way oncologists select patients for immunotherapy. view more

    Research Areas: integrative mutli-omic analyses, Cancer genomics, liquid biopsies, tumor evolution, lung cancer, immunogenomic biomarkers
  • Robert Anders Lab

    Lab Website

    Dr. Anders’ laboratory focuses on the basic processes that lead to cancer. His team approaches these questions through the use of both experimental models and examination of human tissues. His team is specifically interested in interrogating the immune microenvironment of cancer, detecting circulating cancer cells and preventing cancer metastasis.

    Research Areas: cancer, translational research, immunotherapy, liver cancer
  • Suzanne Topalian Lab

    Principal Investigator:
    Suzanne Topalian, M.D.
    Oncology

    Our lab currently focuses on three areas of immunotherapy research: gaining a deeper knowledge of the biological underpinnings of human autoimmune response; discovering biomarkers that will help us identify which patients and tumor types are most likely to respond to various immune therapies; and developing immune-based treatment combinations that could deliver a more powerful anti-tumor response than monotherapies.

    Research Areas: cancer, PD-1, melanoma, immunotherapy, cancer immunology
  • Victor Velculescu Lab

    Lab Website

    The lab currently focuses on identifying genetic alterations in cancer affecting sensitivity and resistance to targeted therapies, and connecting such changes to key clinical characteristics and novel therapeutic approaches. We have recently developed methods that allow noninvasive characterization of cancer, including the PARE method that provided the first whole genome analysis of tumor DNA in the circulation of cancer patients. These analyses provide a window into real-time genomic analyses of cancer patients and provide new avenues for personalized diagnostic and therapeutic intervention.

    Research Areas: cancer, genomics, immunotherapy
  1. 1
  2. 2
Create lab profile
Edit lab profile
back to top button